INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
860-787-7968
Ralph.Giacobbe@TheCignaGroup.com
MEDIA CONTACT:
Justine Sessions
860-810-6523
Justine.Sessions@Evernorth.com
The Cigna Group Reports Strong Third Quarter 2024 Results, Reaffirms 2024 Adjusted EPS Outlook
| • |
Total revenues for the third quarter 2024 increased 30% to $63.7 billion
|
| • |
Shareholders’ net income for the third quarter 2024 was $0.7 billion, or $2.63 per share
|
| • |
Adjusted income from operations1 for the third quarter 2024 was $2.1 billion, or $7.51 per share
|
| • |
Reaffirms 2024 outlook2 for adjusted income from operations1,2 of at least $28.40 per share
|
BLOOMFIELD, CT, October 31, 2024 – Global health company The Cigna Group (NYSE: CI) today reported strong
third quarter
2024 results demonstrating focused execution across Evernorth Health Services and Cigna Healthcare.
“Our strong performance this quarter is a testament to the leadership, stability and
expertise of our team,” said David M. Cordani, chairman and CEO of The Cigna Group. “Our disciplined execution of our strategic plan and our comprehensive health services ensure we remain well-positioned in a highly dynamic environment, while
sustaining business growth in both the near- and long-term.”
Shareholders’ net income for third quarter 2024 was $0.7 billion, or $2.63 per share, including a non-cash
after-tax investment loss of $1.0 billion, or $3.69 per share related to VillageMD. This compares with $1.4
billion, or $4.74 per share, for third quarter 2023.
The Cigna Group's adjusted income from operations1 for third quarter 2024 was $2.1 billion, or $7.51
per share, compared with $2.0 billion, or $6.77 per share, for third quarter 2023, reflecting strong contributions from Evernorth Health Services, particularly within Specialty and Care
Services.
A reconciliation of shareholders’ net income to adjusted income from operations1 is provided on the following page and on Exhibit 1 of this earnings
release.
CONSOLIDATED HIGHLIGHTS
The following table includes highlights of results and reconciliations of
total revenues to adjusted revenues3 and shareholders’ net income (loss) to adjusted income from operations1:
|
Consolidated Financial Results (dollars in millions):
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
|
September 30,
|
|
|
June 30,
|
|
|
September 30,
|
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2024
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues
|
|
$
|
63,694
|
|
|
$
|
49,048
|
|
|
$
|
60,523
|
|
|
$
|
181,472
|
|
|
Net Realized Investment Results from Equity Method Investments3
|
|
|
(177
|
)
|
|
|
30
|
|
|
|
(53
|
)
|
|
|
(238
|
)
|
|
Special Item related to Impairment of dividend receivable3
|
|
|
182
|
|
|
|
- |
|
|
|
- |
|
|
|
182
|
|
|
Adjusted Revenues3
|
|
$
|
63,699
|
|
|
$
|
49,078
|
|
|
$
|
60,470
|
|
|
$
|
181,416
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Earnings, net of taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ Net Income
|
|
$
|
739
|
|
|
$
|
1,408
|
|
|
$
|
1,548
|
|
|
$
|
2,010
|
|
|
Net Realized Investment (Gains) Losses1
|
|
|
740
|
|
|
|
41
|
|
|
|
(20
|
)
|
|
|
2,547
|
|
|
Amortization of Acquired Intangible Assets1
|
|
|
333
|
|
|
|
363
|
|
|
|
317
|
|
|
|
972
|
|
|
Special Items1
|
|
|
300
|
|
|
|
199
|
|
|
|
64
|
|
|
|
367
|
|
|
Adjusted Income from Operations1
|
|
$
|
2,112
|
|
|
$
|
2,011
|
|
|
$
|
1,909
|
|
|
$
|
5,896
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ Net Income, per share
|
|
$
|
2.63
|
|
|
$
|
4.74
|
|
|
$
|
5.45
|
|
|
$
|
7.05
|
|
|
Adjusted Income from Operations1, per share
|
|
$
|
7.51
|
|
|
$
|
6.77
|
|
|
$
|
6.72
|
|
|
$
|
20.68
|
|
| • |
Total revenues for third quarter 2024 increased
30% from third quarter 2023,
primarily driven by significant growth in Evernorth Health Services, reflecting large client wins and strong specialty volume growth.
|
| • |
Adjusted income from operations1 for third quarter 2024 increased 5% from third quarter 2023, reflecting strong contributions from Evernorth Health Services, particularly within Specialty and Care Services, partially offset by lower net investment income.
|
| • |
The SG&A expense ratio4 and adjusted SG&A expense ratio4 were 5.6% and 5.5%, respectively, for third quarter 2024, compared to 7.7% and 7.3%, respectively, in third quarter 2023, reflecting business mix shift, strong revenue growth, and continued operating efficiency.
|
The following table summarizes The Cigna Group’s medical customers and overall customer relationships:
Customer Relationships (in thousands):
| |
|
As of the Periods Ended
|
|
| |
|
September 30,
|
|
|
June 30,
|
|
|
December 31,
|
|
| |
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Pharmacy Customers5
|
|
|
119,996
|
|
|
|
98,325
|
|
|
|
122,470
|
|
|
|
98,570
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Healthcare
|
|
|
17,406
|
|
|
|
17,979
|
|
|
|
17,404
|
|
|
|
18,170
|
|
|
International Health
|
|
|
1,642
|
|
|
|
1,628
|
|
|
|
1,639
|
|
|
|
1,610
|
|
|
Total Medical Customers5
|
|
|
19,048
|
|
|
|
19,607
|
|
|
|
19,043
|
|
|
|
19,780
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behavioral Care
|
|
|
23,662
|
|
|
|
25,100
|
|
|
|
23,816
|
|
|
|
24,956
|
|
|
Dental
|
|
|
18,251
|
|
|
|
18,593
|
|
|
|
18,339
|
|
|
|
18,543
|
|
|
Medicare Part D
|
|
|
2,557
|
|
|
|
2,544
|
|
|
|
2,564
|
|
|
|
2,550
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Customer Relationships5
|
|
|
183,514
|
|
|
|
164,169
|
|
|
|
186,232
|
|
|
|
164,399
|
|
| • |
Total customer relationships5 at September 30, 2024 increased 12% from December 31, 2023 to 183.5 million.
|
| • |
Total pharmacy customers5 at September 30, 2024 increased 22% from December 31, 2023 to 120.0 million due to new sales and
the continued expansion of relationships.
|
| • |
Total medical customers5 at September 30, 2024 were 19.0 million, primarily reflecting a year-to-date decrease in Individual and Family Plans customers, driven by targeted pricing actions in certain geographies.
|
HIGHLIGHTS OF SEGMENT RESULTS
See Exhibit 1 for a reconciliation of adjusted income from operations1 to shareholders’ net income.
Evernorth Health Services
This segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which partner with health plans, employers,
governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions.
Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy
network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases,
specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care delivery and management solutions.
|
Financial Results (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
|
September 30,
|
|
|
June 30,
|
|
|
September 30,
|
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2024
|
|
|
Total adjusted revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmacy Benefit Services
|
|
$
|
28,785
|
|
|
$
|
19,158
|
|
|
$
|
26,612
|
|
|
$
|
81,492
|
|
|
Specialty and Care Services
|
|
$
|
23,812
|
|
|
$
|
19,375
|
|
|
$
|
22,871
|
|
|
$
|
66,755
|
|
|
Net investment income3
|
|
$
|
40
|
|
|
$
|
63
|
|
|
$
|
65
|
|
|
$
|
164
|
|
|
Adjusted Revenues3
|
|
$
|
52,637
|
|
|
$
|
38,596
|
|
|
$
|
49,548
|
|
|
$
|
148,411
|
|
|
Adjusted Income from Operations, Pre-Tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmacy Benefit Services
|
|
$
|
1,011
|
|
|
$
|
981
|
|
|
$
|
798
|
|
|
$
|
2,322
|
|
|
Specialty and Care Services
|
|
$
|
825
|
|
|
$
|
672
|
|
|
$
|
756
|
|
|
$
|
2,369
|
|
|
Net investment income3
|
|
$
|
40
|
|
|
$
|
63
|
|
|
$
|
65
|
|
|
$
|
164
|
|
|
Adjusted Income from Operations, Pre-Tax1
|
|
$
|
1,876
|
|
|
$
|
1,716
|
|
|
$
|
1,619
|
|
|
$
|
4,855
|
|
|
Adjusted Margin, Pre-Tax6
|
|
|
3.6
|
%
|
|
|
4.4
|
%
|
|
|
3.3
|
%
|
|
|
3.3
|
%
|
| • |
Evernorth Health Services third quarter 2024 adjusted revenues3 and adjusted income from operations, pre-tax1, increased 36% and 9%, respectively, relative to third quarter 2023.
|
| • |
For Pharmacy Benefit Services third quarter 2024
relative to third quarter 2023:
|
|
◦ |
Adjusted revenues3 increased 50%, reflecting client wins and organic growth.
|
|
◦ |
Adjusted income from operations, pre-tax1, increased 3%, reflecting continued affordability improvements,
partially offset by planned investments to support new and existing client growth.
|
| • |
For Specialty and Care Services third quarter 2024
relative to third quarter 2023:
|
|
◦ |
Adjusted revenues3 increased 23%, reflecting client wins and strong specialty volume growth.
|
|
◦ |
Adjusted income from operations, pre-tax1, increased 23%, reflecting organic growth in specialty businesses and
clinical care services, including increased Humira biosimilar adoption, partially offset by increased investments to support business growth and the continued
advancement of our digital capabilities and solutions.
|
| • |
Evernorth Health Services net investment income was $40 million for third quarter 2024 compared to
$63 million for third quarter 2023. Third quarter 2024 net investment income does not include an accrual for the VillageMD dividend of $33 million.
|
This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to
clients and customers. U.S. Healthcare provides commercial medical plans and specialty benefits and solutions for insured and self-insured clients, Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health
insurance plans. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.
|
Financial Results (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
|
September 30,
|
|
|
June 30,
|
|
|
September 30,
|
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Revenues3,7
|
|
$
|
13,163
|
|
|
$
|
12,768
|
|
|
$
|
13,143
|
|
|
$
|
39,583
|
|
|
Adjusted Income from Operations, Pre-Tax1
|
|
$
|
1,174
|
|
|
$
|
1,222
|
|
|
$
|
1,204
|
|
|
$
|
3,718
|
|
|
Adjusted Margin, Pre-Tax6
|
|
|
8.9
|
%
|
|
|
9.6
|
%
|
|
|
9.2
|
%
|
|
|
9.4
|
%
|
| • |
Third quarter 2024 adjusted revenues3,7 increased 3% relative to third quarter 2023, reflecting premium rate increases to cover expected increases in underlying
medical costs, partially offset by a decrease in Individual and Family Plans customers.
|
| • |
Third quarter 2024 adjusted income from operations, pre-tax1, decreased 4% relative to third quarter 2023, driven by a higher MCR4 and lower net investment income, partially offset by continued operating efficiency.
|
| • |
The Cigna Healthcare MCR4 was 82.8% for third
quarter 2024 compared to 80.5% for third quarter 2023, reflecting business mix and one extra business day in third quarter 2024. Third quarter 2024 MCR4 also reflects effective pricing execution and affordability initiatives.
|
| • |
Cigna Healthcare net medical costs payable8 was $4.93 billion at September 30, 2024, $5.04 billion at June 30, 2024, and $5.09 billion at September 30, 2023. Favorable prior year reserve development on a gross pre-tax basis was $422 million and $237 million for the nine months ended September 30, 2024 and 2023, respectively.
|
Corporate and Other Operations
Corporate reflects interest expense, amounts not allocated to operating segments and includes intersegment eliminations. Additionally, this discussion
includes items reported in Other Operations, which is comprised of Corporate Owned Life Insurance (“COLI”), the Company’s run-off operations and other non-strategic businesses.
|
Financial Results (dollars in millions):
|
|
|
|
|
|
|
Three Months Ended
|
Nine Months
Ended
|
|
|
September 30,
|
June 30,
|
September 30,
|
|
|
2024
|
2023
|
2024
|
2024
|
|
|
|
|
|
|
|
Adjusted (Loss) from Operations, Pre-Tax1
|
$ (431)
|
$ (409)
|
$ (451)
|
$ (1,273)
|
| • |
Third quarter 2024 adjusted loss from operations, pre-tax1, was $431 million compared to $409 million for third quarter 2023, primarily reflecting the impact of higher interest expense.
|
The Cigna Group’s outlook2 for full year 2024 consolidated adjusted income from
operations1,2 is at least $28.40 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2024 dividends.
|
(dollars in millions, except where noted and per share amounts)
|
|
2024 Outlook
|
Projection for Full Year Ending
December 31, 2024
|
|
Adjusted Income from Operations, per share1,2
|
at least $28.40
|
|
Evernorth Adjusted Income from Operations, Pre-Tax1,2
|
at least $7,000
|
|
Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2
|
at least $4,775
|
|
Cigna Healthcare Medical Care Ratio2,4
|
81.7% to 82.5%
|
The foregoing statements represent the Company’s current estimates of The Cigna Group's
2024 consolidated and segment adjusted income from operations
1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors.
Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.
This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations section (https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review third
quarter 2024 results and discuss full year 2024 outlook beginning today at 8:30 a.m. ET.
A link to the conference call is available in the Investor Relations section of The Cigna Group's website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx.
The call-in numbers for the conference call are as follows:
Live Call
(888) 566-1889 (Domestic)
(773) 799-3989
(International)
Passcode: 10312024
Replay
(888) 282-0035 (Domestic)
(203) 369-3602
(International)
It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better
future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health
Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has approximately 184 million customer relationships around the world. Learn more at thecignagroup.com.
Notes:
|
1. |
Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the
underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income (loss). Adjusted income (loss) from operations is defined as shareholders’ net
income (loss) (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and
special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management
believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment
results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income (loss). See Exhibit 1
for a reconciliation of consolidated adjusted income from operations to shareholders’ net income (loss).
|
|
2. |
Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (loss), on a forward-looking basis because it is unable to
predict, without unreasonable effort, certain components thereof including (i) future net realized investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are
beyond The Cigna Group’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.
|
The Company’s outlook excludes the potential effects of any other business combinations that may occur after the date of
this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2024 dividends.
The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business
and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1
trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.
|
3. |
Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted
revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of
accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not
indicative of past or future underlying performance of the business. For the three and nine months ended September 30, 2024, special items reflects an impairment of dividend receivable for VillageMD accrued dividends of $182.0 million.
Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to
total revenues.
|
|
4. |
Operating ratios are defined as follows:
|
|
• |
The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through
guaranteed cost or experience-rated funding arrangements. Changes in percentages may be expressed in basis points ("bps").
|
|
• |
SG&A expense ratio on a GAAP basis for the third quarter 2024 represents enterprise selling, general and administrative expenses of $3,590 million as a percentage of total revenue of
$63.7 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the third
quarter 2023 represents enterprise selling, general and administrative expenses of $3,788
million as a percentage of total revenue of $49.0 billion at a consolidated level.
|
|
• |
Adjusted SG&A expense ratio for the third quarter 2024 represents enterprise selling, general and administrative expenses of $3,513 million excluding special items of $77 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the third quarter 2023 represents enterprise selling, general and administrative expenses of $3,574 million excluding special items of $214 million as a percentage of adjusted revenue at a consolidated level.
|
|
5. |
Customer relationships are defined as follows:
|
|
• |
Total medical customers includes individuals who meet any one of the following criteria: are covered under a medical insurance policy, managed care
arrangement, or service agreement issued by Cigna Healthcare; have access to Cigna Healthcare's provider network for covered services under their medical plan; or have medical claims that are administered by Cigna Healthcare.
|
|
• |
During the fourth quarter of 2023, the U.S. Commercial and U.S. Government operating segments combined to form the U.S. Healthcare operating segment. Information presented for three months ended September 30, 2023 has been restated to conform to the new operating segment
presentation.
|
|
6. |
Adjusted margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.
|
|
7. |
The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company’s
share of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.
|
|
8. |
Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other
recoverables. The gross medical costs payable balance was $5.09 billion as of September 30, 2024,
$5.20 billion as of June 30, 2024, and $5.32 billion as of September 30, 2023.
|
|
9. |
The measure “adjusted effective tax rate” is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure,
“consolidated effective tax rate”. We define adjusted effective tax rate as the consolidated income tax rate applicable to the Company’s pre-tax income excluding pre-tax income (loss) attributable to noncontrolling interests, net realized
investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of
accounting are also excluded. Management is not able to provide a reconciliation to the consolidated effective tax rate on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof
including (i) future net realized investment results and (ii) future special items.
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may
include, among others, statements concerning our projected adjusted income from operations outlook for 2024 on a per share, and segment basis; projected medical care ratio; future dividends, including projected shareholder dividends for 2024;
projected weighted average shares outstanding; future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives;
economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of the developing inflationary and interest rate pressures; capital deployment plans and amounts available
for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify
forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all
forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or
implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our
ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that
are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians,
hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy
provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of
potential cyberattack or other privacy or data security incidents; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational
operations, including currency exchange rates; risks related to an impairment of goodwill, intangible assets and/or investments (including as a result of the failure to realize the expected benefits of strategic transactions, as well as integration
or separation difficulties or underperformance of such transactions relative to expectations); dependence on success of relationships with third parties; risk of significant
disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of
government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of
litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions,
the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our
significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on
Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance
or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except as may be required by law.
|
THE CIGNA GROUP
|
Exhibit 1
|
|
|
COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
Three Months
Ended
|
|
|
|
September 30,
|
|
September 30,
|
|
June 30,
|
|
|
(Dollars in millions, except per share amounts)
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REVENUES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmacy revenues
|
|
$
|
48,284
|
|
$
|
34,531
|
|
$
|
135,421
|
|
$
|
100,639
|
|
$
|
45,101
|
|
|
Premiums
|
|
|
11,436
|
|
|
10,998
|
|
|
34,493
|
|
|
33,062
|
|
|
11,454
|
|
|
Fees and other revenues
|
|
|
3,889
|
|
|
3,198
|
|
|
10,862
|
|
|
9,574
|
|
|
3,647
|
|
|
Net investment income
|
|
|
85
|
|
|
321
|
|
|
696
|
|
|
876
|
|
|
321
|
|
|
Total revenues
|
|
|
63,694
|
|
|
49,048
|
|
|
181,472
|
|
|
144,151
|
|
|
60,523
|
|
|
Net realized investment results from certain equity method investments
|
|
|
(177)
|
|
|
30
|
|
|
(238)
|
|
|
22
|
|
|
(53
|
)
|
|
Special item related to impairment of dividend receivable
|
|
|
182
|
|
|
- |
|
|
182
|
|
|
-
|
|
|
- |
|
|
Adjusted revenues (1)
|
|
$
|
63,699
|
|
$
|
49,078
|
|
$
|
181,416
|
|
$
|
144,173
|
|
$
|
60,470
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' net income
|
|
$
|
739
|
|
$
|
1,408
|
|
$
|
2,010
|
|
$
|
4,135
|
|
$
|
1,548
|
|
|
Pre-tax adjusted income (loss) from operations by segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Evernorth Health Services
|
|
$
|
1,876
|
|
$
|
1,716
|
|
$
|
4,855
|
|
$
|
4,552
|
|
$
|
1,619
|
|
|
Cigna Healthcare
|
|
|
1,174
|
|
|
1,222
|
|
|
3,718
|
|
|
3,509
|
|
|
1,204
|
|
|
Corporate and Other Operations
|
|
|
(431)
|
|
|
(409)
|
|
|
(1,273)
|
|
|
(1,202)
|
|
|
(451
|
)
|
Adjusted income tax expense
|
|
|
(507
|
)
|
|
(518
|
)
|
|
(1,404
|
)
|
|
(1,410
|
)
|
|
(463
|
)
|
|
Consolidated after-tax adjusted income from operations
|
|
$
|
2,112
|
|
$
|
2,011
|
|
$
|
5,896
|
|
$
|
5,449
|
|
$
|
1,909
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares (in thousands)
|
|
|
281,396
|
|
|
297,131
|
|
|
285,042
|
|
|
297,663
|
|
|
284,052
|
|
|
Common shares outstanding (in thousands)
|
|
|
|
|
|
|
|
|
279,839
|
|
|
293,764
|
|
|
279,520
|
|
|
SHAREHOLDERS' EQUITY at September 30,
|
|
|
|
|
|
|
|
$
|
42,095
|
|
$
|
45,691
|
|
|
|
|
|
SHAREHOLDERS' EQUITY PER SHARE at September 30,
|
|
|
|
|
|
|
|
$
|
150.43
|
|
$
|
155.54
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
Three Months Ended
|
|
| |
|
September 30,
|
|
September 30,
|
|
June 30,
|
|
| |
|
2024 |
|
2023
|
|
2024 |
|
2023
|
|
2024 |
|
|
(Dollars in millions, except per share amounts)
|
|
Pre-tax
|
|
After-tax
|
|
Pre-tax
|
After-tax
|
|
Pre-tax
|
|
After-tax
|
|
Pre-tax
|
|
After-tax
|
|
Pre-tax
|
|
After-tax
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS' NET INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' net income
|
|
|
|
$
|
739
|
|
|
|
$
|
1,408
|
|
|
|
$
|
2,010
|
|
|
|
$
|
4,135
|
|
|
|
$
|
1,548
|
|
|
Adjustments to reconcile adjusted income from operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized investment losses (gains) (2)
|
|
$
|
744
|
|
|
740
|
$ |
44
|
|
|
41
|
|
$
|
2,567
|
|
|
2,547
|
|
$
|
66
|
|
|
56
|
|
$
|
(5)
|
|
|
(20
|
)
|
|
Amortization of acquired intangible assets
|
|
|
436
|
|
|
333
|
|
454
|
|
|
363
|
|
|
1,279
|
|
|
972
|
|
|
1,368
|
|
|
1,053
|
|
|
420
|
|
|
317
|
|
|
Special Items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment of dividend receivable
|
|
|
182
|
|
|
138
|
|
- |
|
|
-
|
|
|
182
|
|
|
138
|
|
|
- |
|
|
- |
|
|
-
|
|
|
- |
|
|
Integration and transaction-related costs
|
|
|
77
|
|
|
59
|
|
13
|
|
|
9
|
|
|
177
|
|
|
135
|
|
|
20
|
|
|
15
|
|
|
63
|
|
|
47
|
|
|
Loss on sale of businesses
|
|
|
87
|
|
|
62
|
|
21
|
|
|
19
|
|
|
106
|
|
|
19
|
|
|
21
|
|
|
19
|
|
|
- |
|
|
- |
|
|
Deferred tax expenses, net
|
|
|
-
|
|
|
41
|
|
- |
|
|
-
|
|
|
-
|
|
|
75
|
|
|
- |
|
|
- |
|
|
- |
|
|
17
|
|
|
Charges associated with litigation matters
|
|
|
- |
|
|
- |
|
201
|
|
|
171
|
|
|
- |
|
|
- |
|
|
201
|
|
|
171
|
|
|
- |
|
|
- |
|
|
Adjusted income from operations (3)
|
|
|
|
|
$
|
2,112
|
|
|
|
$
|
2,011
|
|
|
|
|
$
|
5,896
|
|
|
|
|
$
|
5,449
|
|
|
|
|
$
|
1,909
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DILUTED EARNINGS PER SHARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' net income
|
|
|
|
|
$
|
2.63
|
|
|
|
$
|
4.74
|
|
|
|
|
$
|
7.05
|
|
|
|
|
$
|
13.89
|
|
|
|
|
$
|
5.45
|
|
|
Adjustments to reconcile to adjusted income from operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized investment losses (gains) (2)
|
|
$
|
2.64
|
|
|
2.63
|
$
|
0.15
|
|
|
0.14
|
|
$
|
9.00
|
|
|
8.93
|
|
$
|
0.22
|
|
|
0.19
|
|
$
|
(0.02)
|
|
|
(0.07
|
)
|
|
Amortization of acquired intangible assets
|
|
|
1.55
|
|
|
1.18
|
|
1.53
|
|
|
1.22
|
|
|
4.49
|
|
|
3.41
|
|
|
4.60
|
|
|
3.54
|
|
|
1.48
|
|
|
1.11
|
|
|
Special Items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment of dividend receivable
|
|
|
0.65
|
|
|
0.49
|
|
- |
|
|
- |
|
|
0.64
|
|
|
0.48
|
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
Integration and transaction-related costs
|
|
|
0.27
|
|
|
0.21
|
|
0.04
|
|
|
0.03
|
|
|
0.62
|
|
|
0.48
|
|
|
0.07
|
|
|
0.05
|
|
|
0.22
|
|
|
0.17
|
|
|
Loss on sale of businesses
|
|
|
0.31
|
|
|
0.22
|
|
0.07
|
|
|
0.06
|
|
|
0.37
|
|
|
0.07
|
|
|
0.07
|
|
|
0.06
|
|
|
- |
|
|
- |
|
|
Deferred tax expenses, net
|
|
|
- |
|
|
0.15
|
|
- |
|
|
- |
|
|
- |
|
|
0.26
|
|
|
- |
|
|
- |
|
|
- |
|
|
0.06
|
|
|
Charges associated with litigation matters
|
|
|
- |
|
|
- |
|
0.68
|
|
|
0.58
|
|
|
- |
|
|
- |
|
|
0.67
|
|
|
0.58
|
|
|
-
|
|
|
- |
|
|
Adjusted income from operations
|
|
|
|
|
$
|
7.51
|
|
|
|
$
|
6.77
|
|
|
|
|
$
|
20.68
|
|
|
|
|
$
|
18.31
|
|
|
|
|
$
|
6.72
|
|
| |
(1)
|
Adjusted revenues is defined as total revenues excluding the following
adjustments: special items and The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they
are not indicative of past or future underlying performance of our businesses.
|
| |
(2)
|
Includes Net realized investment losses/gains as presented in our
Consolidated Statements of Income, as well as the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within
Fees and other revenues in our Consolidated Statements of Income.
|
| |
(3)
|
Adjusted income (loss) from operations is defined as shareholders’ net
income (loss) (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net realized investment results, amortization of
acquired intangible assets and special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.
|